These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Johnson MD; Anderson BD Pharm Res; 1996 Dec; 13(12):1881-6. PubMed ID: 8987089 [TBL] [Abstract][Full Text] [Related]
23. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase. Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420 [TBL] [Abstract][Full Text] [Related]
24. Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R-nonyl)adenine [(+)-EHNA]. Pragnacharyulu PV; Varkhedkar V; Curtis MA; Chang IF; Abushanab E J Med Chem; 2000 Nov; 43(24):4694-700. PubMed ID: 11101360 [TBL] [Abstract][Full Text] [Related]
25. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Anderson BD; Morgan ME; Singhal D Pharm Res; 1995 Aug; 12(8):1126-33. PubMed ID: 7494823 [TBL] [Abstract][Full Text] [Related]
27. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine. Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142 [TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Russell JW; Klunk LJ Biochem Pharmacol; 1989 May; 38(9):1385-8. PubMed ID: 2497744 [TBL] [Abstract][Full Text] [Related]
29. The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation. Kayhan N; Funke B; Conzelmann LO; Winkler H; Hofer S; Steppan J; Schmidt H; Bardenheuer H; Vahl CF; Weigand MA Crit Care; 2008; 12(5):R125. PubMed ID: 18847498 [TBL] [Abstract][Full Text] [Related]
30. Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine. Ahluwalia GS; Cooney DA; Shirasaka T; Mitsuya H; Driscoll JS; Johns DG Mol Pharmacol; 1994 Nov; 46(5):1002-8. PubMed ID: 7969062 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Woodson JC; Minor TR; Job RF Behav Neurosci; 1998 Apr; 112(2):399-409. PubMed ID: 9588486 [TBL] [Abstract][Full Text] [Related]
32. Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors. Kandalkar SR; Ramaiah PA; Joshi M; Wavhal A; Waman Y; Raje AA; Tambe A; Ansari S; De S; Palle VP; Mookhtiar KA; Deshpande AM; Barawkar DA Bioorg Med Chem; 2017 Oct; 25(20):5799-5819. PubMed ID: 28951094 [TBL] [Abstract][Full Text] [Related]
33. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608 [TBL] [Abstract][Full Text] [Related]
34. Erythroid differentiation and growth inhibition of K562 cells by 2',5'-dideoxyadenosine: synergism with interferon-alpha. Ogawa K; Tashima M; Takeda Y; Sawai H; Toi T; Sawada H; Maruyama Y; Okuma M Leuk Res; 1995 Oct; 19(10):749-55. PubMed ID: 7500653 [TBL] [Abstract][Full Text] [Related]
35. Determination of 2'-beta-fluoro-2',3'-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography. Roth JS; Ford H; Tanaka M; Mitsuya H; Kelley JA J Chromatogr B Biomed Sci Appl; 1998 Aug; 712(1-2):199-210. PubMed ID: 9698243 [TBL] [Abstract][Full Text] [Related]
36. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase. Caiolfa VR; Gill D; Parola AH FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576 [TBL] [Abstract][Full Text] [Related]
37. Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury. Abd-Elfattah AS; Jessen ME; Lekven J; Wechsler AS Mol Cell Biochem; 1998 Mar; 180(1-2):179-91. PubMed ID: 9546645 [TBL] [Abstract][Full Text] [Related]
38. The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. Antonioli L; Fornai M; Colucci R; Awwad O; Ghisu N; Tuccori M; Da Settimo F; La Motta C; Natale G; Duranti E; Virdis A; Blandizzi C J Pharmacol Exp Ther; 2010 Nov; 335(2):434-42. PubMed ID: 20668053 [TBL] [Abstract][Full Text] [Related]
39. Phosphoramidate derivatives of 2',5'-dideoxyadenosine as potential inhibitors of the EDHF phenomenon. Gavazza F; Daverio F; Chaytor AT; Griffith TM; McGuigan C Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):553-5. PubMed ID: 16247988 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. Antonioli L; Fornai M; Colucci R; Ghisu N; Da Settimo F; Natale G; Kastsiuchenka O; Duranti E; Virdis A; Vassalle C; La Motta C; Mugnaini L; Breschi MC; Blandizzi C; Del Taca M J Pharmacol Exp Ther; 2007 Aug; 322(2):435-42. PubMed ID: 17488880 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]